Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered ...
Learn more We’ve covered plenty of interesting new whiskey releases in 2024 across various styles and price points. But Jim Beam’s newly revealed Winter Reserve looks to be in pole position as the ...
Beam Therapeutics has acknowledged the death of a patient in a Phase I/II trial assessing the base editing therapy candidate BEAM-101—a death the company said was likely caused by the ...
Soumit Roy from JonesTrading reiterated a Hold rating on Beam Therapeutics (BEAM – Research Report). The company’s shares closed today at $23.93. According to TipRanks, Roy is an analyst with ...
In a report released today, Greg Harrison from Scotiabank maintained a Hold rating on Beam Therapeutics (BEAM – Research Report), with a price target of $24.00. The company’s shares closed ...
According to the brand, Baker’s High-Rye Bourbon has twice as much rye as regular Baker’s, which would put it at just about the same mashbill as Basil Hayden and Old Grand-Dad. So how does it ...